Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. News about Spero often centers on its lead investigational product, tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem antibiotic candidate for complicated urinary tract infections (cUTI), including pyelonephritis.
Readers following SPRO news can expect updates on clinical trial milestones, such as the pivotal Phase 3 PIVOT-PO trial, which Spero and its partner GSK reported met its primary endpoint and was stopped early for efficacy. Coverage also includes presentations of clinical data at major infectious disease conferences like IDWeek, where late-breaking results and detailed efficacy and safety analyses for tebipenem HBr have been shared.
Spero’s news flow also features regulatory and partnership developments. This includes announcements that GSK plans to, and has, submitted or resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for tebipenem HBr in cUTI, including pyelonephritis, as well as disclosures about milestone payments to Spero triggered by these filings under the exclusive license agreement between the companies.
In addition, Spero regularly reports its quarterly operating results and business updates, detailing collaboration revenue, grant funding, research and development spending, and cash runway expectations. Corporate governance and capital markets news, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), amendments to stock incentive plans, and outcomes of annual stockholder meetings, also appear in the company’s announcements.
For investors, clinicians, and observers interested in antibiotic development, MDR infections, and rare disease therapeutics, the SPRO news page provides a consolidated view of Spero’s clinical progress, regulatory interactions, financial updates, and key collaborations over time.
Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug-resistant bacterial infections, will participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event will take place on May 20, 2024, at NASDAQ World Headquarters in New York, NY. During the conference, Spero's President and CEO, Sath Shukla, will engage in a fireside chat and one-on-one meetings. The session is scheduled from 1:30 - 2:00 PM ET and will be accessible via webcast on Spero's website, with a replay available post-event.
Spero Therapeutics (Nasdaq: SPRO) reported its Q1 2024 financial results and provided a business update. The company continues advancing its clinical pipeline, with key trials underway. Topline data for SPR720, aimed at treating NTM-PD, is expected in 2H 2024. The Phase 3 trial for tebipenem HBr in cUTI is ongoing, with enrollment completion targeted for 2H 2025. SPR206 received FDA Fast Track designation for HABP/VABP treatment.
Spero reported a net loss of $12.7 million for Q1 2024, a slight improvement from $13.3 million a year ago. Revenue surged to $9.3 million, primarily due to increased collaboration and grant revenues. R&D expenses rose to $17.3 million, reflecting heightened clinical activity. G&A expenses decreased to $5.9 million. The company's cash balance stands at $82.3 million, up from $76.3 million at year-end 2023, bolstered by a $23.8 million milestone payment from GSK. Spero's financial runway is expected to extend into late 2025.
Spero Therapeutics, Inc. (Nasdaq: SPRO) will report its first quarter 2024 financial results and business update on May 15, 2024. The company focuses on developing treatments for rare diseases and MDR bacterial infections.
Spero Therapeutics, Inc. announced the approval of 10,833 restricted stock unit awards to a new employee under the 2019 Inducement Plan. The RSUs will vest in four equal annual installments beginning on May 1, 2025, subject to the employee's continued employment.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.